| [1] |
王春霞, 葛俊李, 李芳, 等. 中药治疗溃疡性结肠炎作用及机制研究进展[J]. 中国实验方剂学杂志, 2023, 29(2):270-282.
|
| [2] |
GAJENDRAN M, LOGANATHAN P, JIMENEZ G, et al. A comprehensive review and update on ulcerative colitis[J]. Dis Mon, 2019, 65(12):100851.
DOI
URL
|
| [3] |
GROS B, KAPLAN G G. Ulcerative colitis in adults:a review[J]. JAMA, 2023, 330(10):951-965.
DOI
URL
|
| [4] |
KAENKUMCHORN T, WAHBEH G. Ulcerative colitis:making the diagnosis[J]. Gastroenterol Clin North Am, 2020, 49(4):655-669.
DOI
URL
|
| [5] |
石鹏辉, 范伟光, 张珍, 等. CXCR5、sPD-1、Hcy在AIDS患者治疗过程中的动态变化及临床意义[J]. 检验医学, 2022, 37(2):103-107.
DOI
|
| [6] |
BERNARDI S, VOLTAN R, RIMONDI E, et al. TRAIL,OPG,and TWEAK in kidney disease:biomarkers or therapeutic targets?[J]. Clin Sci(Lond), 2019, 133(10):1145-1166.
DOI
URL
|
| [7] |
ZAITSEVA O, HOFFMANN A, OTTO C, et al. Targeting fibroblast growth factor(FGF)-inducible 14(Fn14)for tumor therapy[J]. Front Pharmacol, 2022,13:935086.
|
| [8] |
中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中华炎性肠病杂志(中英文), 2018, 2(3):173-190.
|
| [9] |
SZÉLES Á, FAZEKAS T, VÁNCSA S, et al. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy:a systematic review and meta-analysis[J]. Cancer Immunol Immunother, 2023, 72(5):1061-1073.
DOI
|
| [10] |
WU D, LIU Y, PANG N, et al. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients[J]. Medicine(Baltimore), 2019, 98(43):e17608.
|
| [11] |
BRUNET-RATNASINGHAM E, MOROU A, DUBÉ M, et al. Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function[J]. EBioMedicine, 2022,84:104254.
|
| [12] |
谭宁, 刘建湘, 亢倩, 等. 慢性乙型肝炎临床治愈者的血清sPD-1和sPD-L1水平及临床特点[J]. 临床肝胆病杂志, 2023, 39(1):50-55.
|
| [13] |
GUO Y, REN M, GE L, et al. Increased serum concentrations of TNF-like weak inducer of apoptosis predict higher 28-day mortality in patients with sepsis[J]. Emerg Med Int, 2019,2019:7238705.
|
| [14] |
DA SILVA-CANDAL A, CUSTODIA A, LÓPEZ-DEQUIDT I, et al. sTWEAK is a leukoaraiosis biomarker associated with neurovascular angiopathy[J]. Ann Clin Transl Neurol, 2022, 9(2):171-180.
DOI
URL
|
| [15] |
张鑫, 王慧, 刘肃, 等. 两种血清指标联合检测对非心脏手术围术期心脏不良事件发生的预测价值分析[J]. 中华老年心脑血管病杂志, 2021, 23(11):1177-1179.
|
| [16] |
COMERTPAY E, VURAL S, EROĞLU O, et al. The diagnostic value of sTWEAK in acute ischemic stroke[J]. Balkan Med J, 2020, 37(6):336-340.
|
| [17] |
MIRIOGLU S, CINAR S, YAZICI H, et al. Serum and urine TNF-like weak inducer of apoptosis,monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus[J]. Lupus, 2020, 29(4):379-388.
DOI
URL
|
| [18] |
MA H Y, CHEN S, CAO W D, et al. Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus:a systematic review and meta-analysis[J]. Ren Fail, 2021, 43(1):20-31.
DOI
URL
|